XML 74 R49.htm IDEA: XBRL DOCUMENT v3.25.3
Collaboration and License Agreements - Amgen, Inc. (Details)
Sep. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2016
agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Deferred revenue $ 2,399,000 $ 0  
Amgen | Olpasiran Agreement      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Number of agreements | agreement     2
Contract assets 0    
Deferred revenue 0    
Amgen | Olpasiran Agreement | Maximum      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Additional remaining development regulatory and sales milestones payments $ 485,000,000.0